Department of General Surgical Science, Gunma University, Graduate School of Medicine, Maebashi, Japan
Department of Innovative Immune-Oncology Therapeutics, Gunma University, Graduate School of Medicine, Maebashi, Japan.
Anticancer Res. 2020 Jan;40(1):261-269. doi: 10.21873/anticanres.13948.
Pulmonary pleomorphic carcinoma (PPC) is a rare aggressive neoplasm, with dismal prognosis. Whether tumor immunity is associated with the progressive biological behavior of PPC remains unclear. The purpose of this study was to examine the prognostic significance of tumor immunity-related markers such as programmed death-1 ligand (PD-L1) and CD4 or CD8 tumor-infiltrating lymphocytes (TILs) in patients with surgically resected PPC.
Ninety-nine patients with surgically resected PPC were assessed by immunohistochemistry. The expression of PD-L1, CD4, and CD8 was examined in specimens of the resected tumors.
PD-L1 was highly expressed in 61% (60/99) of lesions and high expression of CD4 and CD8 was identified in 42% (42/99) and 51% (51/99) of lesions, respectively. There was no relationship between the expression PD-L1 and the numbers of CD4 or CD8 TILs. The expression of PD-L1 was not identified as a significant prognostic marker; however, a low number of CD4 TILs was identified as an independent marker for predicting a worse outcome after surgical resection of PPC, especially in patients with an epithelial component of adenocarcinoma or early stage of disease. By univariate analysis, a low number of CD8 TILs was found to be a significant prognostic marker linked to poor overall survival in patients with non-adenocarcinoma components.
A low number of CD4 TILs is an independent marker for predicting a favorable prognosis after surgical resection in patients with PPC, especially in patients with adenocarcinoma components or early stage of disease.
肺多形性癌(PPC)是一种罕见的侵袭性肿瘤,预后不良。肿瘤免疫是否与 PPC 的进行性生物学行为有关尚不清楚。本研究旨在探讨程序性死亡配体-1 (PD-L1)和 CD4 或 CD8 肿瘤浸润淋巴细胞(TIL)等肿瘤免疫相关标志物在接受手术切除 PPC 的患者中的预后意义。
对 99 例接受手术切除 PPC 的患者进行免疫组织化学评估。检查了切除肿瘤标本中 PD-L1、CD4 和 CD8 的表达情况。
61%(60/99)的病变中 PD-L1 高表达,42%(42/99)和 51%(51/99)的病变中 CD4 和 CD8 高表达。PD-L1 的表达与 CD4 或 CD8 TIL 的数量之间没有关系。PD-L1 的表达不能作为显著的预后标志物;然而,CD4 TIL 的数量较少被确定为预测 PPC 手术后结局较差的独立标志物,尤其是在具有腺癌上皮成分或疾病早期的患者中。通过单因素分析,发现 CD8 TIL 数量较少是与非腺癌成分患者总生存不良相关的显著预后标志物。
在 PPC 患者中,CD4 TIL 数量较少是手术切除后预测预后良好的独立标志物,尤其是在具有腺癌成分或疾病早期的患者中。